炎性乳腺癌术前治疗后乳腺皮肤MRI变化与病理缓解及可切除性的关系
该回顾性研究纳入76例炎性乳腺癌患者的152次基线及术前系统治疗(PST)后乳腺MRI,按ACR-BIRADS MRI词典评估皮肤厚度、强化及动力学,并与乳房切除术后皮肤病理缓解相关。PST后皮肤厚度显著下降,但多数患者仍有残留皮肤增厚;有无皮肤残留肿瘤者PST后中位厚度分别为4.7 mm与3.0 mm(p=0.008)。PST后MRI皮肤厚度与局部区域复发(LRR)率无关联。
要点
- IBC基线MRI均见皮肤增厚(76/76),99%(75/76)有皮肤强化,72%(54/75)为中等/快速初始动力学。
- PST后87%(66/76)仍有皮肤增厚,84%(64/76)厚度较基线下降;43%(33/76)皮肤强化持续存在。
- PST后MRI皮肤厚度与LRR率无关,皮肤改变持续存在不排除成功PST后行乳房切除术。
核心结论
- IBC患者基线乳腺MRI常见皮肤增厚和强化,成功的PST后皮肤厚度有统计学显著下降,但多数患者MRI上皮肤改变持续存在。
- PST后乳腺MRI皮肤厚度与LRR率无关联;达到部分或完全实质缓解的患者即使MRI皮肤改变持续,仍可接受乳房切除术且LRR率低。
研究设计与样本
- 回顾性研究,纳入76例IBC患者的152次基线和PST后乳腺MRI。
- 采用ACR-BIRADS MRI词典评估皮肤厚度、定性强化和动力学分析。
- 参考标准为乳房切除术时皮肤病理缓解,并分析PST后MRI皮肤厚度与LRR率的关系。
关键影像表现/征象
- 基线MRI所有76例(100%)均见皮肤增厚,75/76(99%)有皮肤强化。
- 基线皮肤强化者中54/75(72%)为中等/快速初始动力学,其中49/54(91%)通常呈持续延迟动力学。
- PST后66/76(87%)有残留皮肤增厚,64/76(84%)皮肤厚度较基线下降,33/76(43%)皮肤强化持续存在。
- PST后皮肤有残留肿瘤者中位厚度4.7 mm,无残留肿瘤者3.0 mm(p=0.008)。
- 无论病理缓解如何,PST后多数患者MRI皮肤增厚持续存在:有残留肿瘤者100%(14/14),无残留肿瘤者84%(52/62)。
诊断标准与关键数值
- 采用ACR-BIRADS MRI词典评估皮肤厚度、定性强化和动力学分析。
- PST后皮肤有残留肿瘤者中位厚度4.7 mm,无残留肿瘤者3.0 mm(p=0.008)。
- PST后MRI皮肤厚度与LRR率无关联。
临床应用与阅片要点
- 阅片时按ACR-BIRADS MRI词典报告皮肤厚度、强化及动力学,基线IBC常见皮肤增厚和强化。
- PST后皮肤增厚和强化可持续存在,尤其无残留肿瘤者84%仍有增厚,不应仅凭此判断治疗失败或不可手术。
- PST后皮肤厚度与LRR无关,评估可切除性应结合实质缓解情况,避免过度解读残留皮肤改变。
局限性
- 回顾性研究设计。
- 单中心研究,样本量76例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Preoperative systemic therapy (PST) followed by mastectomy and radiation improves survival for patients with inflammatory breast cancer (IBC). Residual disease within the skin post-PST adversely impacts surgical outcome and risk of local-regional recurrence (LRR). We aimed to assess magnetic resonance imaging (MRI) breast skin changes post-PST with pathologic response and its impact on surgical resectability.
MATERIALS AND METHODS: We retrospectively reviewed 152 baseline and post-PST breast MRIs of 76 patients with IBC. Using the ACR-BIRADS MRI lexicon, we correlated skin thickness, qualitative enhancement, and kinetic analysis with pathologic response in the skin at mastectomy.
RESULTS: Baseline MRI showed skin thickening in all 76 patients, 75/76 (99%) showed skin enhancement, 54/75 (72%) had medium/fast initial kinetics, usually with persistent delayed kinetics in 49/54 (91%). Following PST, 66/76 (87%) had residual skin thickening with 64/76 (84%) showing a decrease; 33/76 (43%) had persistent enhancement. The median thickness post-PST was 4.7 mm with residual tumor in the skin, and 3.0 mm without residual tumor (p = 0.008). Regardless of pathologic response, the majority of patients had persistent skin thickening on MRI following PST (100% [14/14] with residual tumor and 84% [52/62] without residual tumor). There was no association between post-PST skin thickness on breast MRI and rate of LRR.
CONCLUSION: Patients with IBC have skin thickening and enhancement on baseline breast MRI, with a statistically significant reduction in skin thickness following successful PST. Despite persistent skin changes on MRI, patients achieving a partial or complete parenchymal response to PST may proceed to mastectomy with low LRR rates.
引用
- Yeh E, Rives A, Nakhlis F, et al. MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer. Acad Radiol. 2021. PMID: 34561164. doi:10.1016/j.acra.2021.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。